JP2023552555A - リピドイド組成物およびその使用方法 - Google Patents

リピドイド組成物およびその使用方法 Download PDF

Info

Publication number
JP2023552555A
JP2023552555A JP2023534118A JP2023534118A JP2023552555A JP 2023552555 A JP2023552555 A JP 2023552555A JP 2023534118 A JP2023534118 A JP 2023534118A JP 2023534118 A JP2023534118 A JP 2023534118A JP 2023552555 A JP2023552555 A JP 2023552555A
Authority
JP
Japan
Prior art keywords
lipidoid
lipidoid composition
composition according
cancer
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552555A5 (https=
JPWO2022125589A5 (https=
Inventor
シュィ，チアオビン
チェン，ジンジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of JP2023552555A publication Critical patent/JP2023552555A/ja
Publication of JP2023552555A5 publication Critical patent/JP2023552555A5/ja
Publication of JPWO2022125589A5 publication Critical patent/JPWO2022125589A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023534118A 2020-12-07 2021-12-07 リピドイド組成物およびその使用方法 Pending JP2023552555A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122229P 2020-12-07 2020-12-07
US63/122,229 2020-12-07
PCT/US2021/062273 WO2022125589A1 (en) 2020-12-07 2021-12-07 Lipidoid compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023552555A true JP2023552555A (ja) 2023-12-18
JP2023552555A5 JP2023552555A5 (https=) 2024-12-06
JPWO2022125589A5 JPWO2022125589A5 (https=) 2024-12-06

Family

ID=81973771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534118A Pending JP2023552555A (ja) 2020-12-07 2021-12-07 リピドイド組成物およびその使用方法

Country Status (8)

Country Link
US (1) US20240024466A1 (https=)
EP (1) EP4255432A4 (https=)
JP (1) JP2023552555A (https=)
CN (1) CN116829149A (https=)
AU (1) AU2021397737A1 (https=)
CA (1) CA3201018A1 (https=)
IL (1) IL303434A (https=)
WO (1) WO2022125589A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232684A1 (en) * 2021-04-30 2022-11-03 Trustees Of Tufts College Lipidoid nanoparticles for the treatment of diseases and disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508235A (ja) * 2008-11-07 2012-04-05 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
JP2012526135A (ja) * 2009-05-05 2012-10-25 アルニラム・ファーマシューティカルズ・インコーポレーテッド 脂質組成物
CN109503411A (zh) * 2018-11-02 2019-03-22 中国药科大学 叔胺类阳离子脂质衍生物及其在rna药物递送系统的应用
WO2019152848A1 (en) * 2018-02-01 2019-08-08 Trustees Of Tufts College Lipid-like nanocomplexes and uses thereof
JP2020504764A (ja) * 2016-10-26 2020-02-13 キュアバック アーゲー 脂質ナノ粒子ｍＲＮＡワクチン
WO2020069442A1 (en) * 2018-09-28 2020-04-02 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
US20200109121A1 (en) * 2018-08-31 2020-04-09 Massachusetts Institute Of Technology Ionizable lipidoids and their uses
WO2021202772A1 (en) * 2020-04-01 2021-10-07 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006487B2 (en) * 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US9339029B2 (en) * 2014-09-04 2016-05-17 Preceres Inc. Hydrazinyl lipidoids and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508235A (ja) * 2008-11-07 2012-04-05 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
JP2012526135A (ja) * 2009-05-05 2012-10-25 アルニラム・ファーマシューティカルズ・インコーポレーテッド 脂質組成物
JP2020504764A (ja) * 2016-10-26 2020-02-13 キュアバック アーゲー 脂質ナノ粒子ｍＲＮＡワクチン
WO2019152848A1 (en) * 2018-02-01 2019-08-08 Trustees Of Tufts College Lipid-like nanocomplexes and uses thereof
US20200109121A1 (en) * 2018-08-31 2020-04-09 Massachusetts Institute Of Technology Ionizable lipidoids and their uses
WO2020069442A1 (en) * 2018-09-28 2020-04-02 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
CN109503411A (zh) * 2018-11-02 2019-03-22 中国药科大学 叔胺类阳离子脂质衍生物及其在rna药物递送系统的应用
WO2021202772A1 (en) * 2020-04-01 2021-10-07 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NGUYEN, DAVID N. ET AL.: "Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery", PNAS, JPN6026005646, 15 March 2012 (2012-03-15), pages 797 - 803, ISSN: 0005795111 *

Also Published As

Publication number Publication date
AU2021397737A9 (en) 2025-01-09
EP4255432A1 (en) 2023-10-11
IL303434A (en) 2023-08-01
CA3201018A1 (en) 2022-06-16
EP4255432A4 (en) 2025-11-19
AU2021397737A1 (en) 2023-06-22
US20240024466A1 (en) 2024-01-25
WO2022125589A1 (en) 2022-06-16
CN116829149A (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
US11376324B2 (en) Sting activating nanovaccine for immunotherapy
JP2020196754A (ja) がん及び感染症の治療方法並びに治療用組成物
US9220763B2 (en) Nano-vehicle derived from tumor tissue, and cancer vaccine using same
JP2016535009A (ja) 抗体依存性エキソソーム治療の方法
JP2024528697A (ja) 微細藻類由来の細胞外小胞、その調製および使用
US20240216289A1 (en) Lipidoid nanoparticles for the treatment of diseases and disorders
ES2365988T3 (es) Agentes inmunoestimulantes no específicos.
KR20150064097A (ko) 암을 치료하는 방법
KR20150022996A (ko) 암 면역요법을 위한 조성물 및 방법
TW201000124A (en) Stimulation of an immune response by enantiomers of cationic lipids
TW200902060A (en) Stimulation of an immune response by cationic lipids
JP7304855B2 (ja) 新規イミダゾピリミジン化合物およびそれらの使用
JP7098520B2 (ja) 細胞傷害性免疫刺激性粒子及びその使用
JP2024516353A (ja) がんの治療のための併用療法
KR20240046744A (ko) 면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법
JP2023552555A (ja) リピドイド組成物およびその使用方法
JP7048102B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
KR20260018046A (ko) 이전의 면역 관문 억제제 노출 이력이 있는 대상체의 암 치료 방법
KR20260018053A (ko) Bcl2 억제제에 노출 이력이 없는 대상체의 암 치료 방법
US12611456B2 (en) Use of thiazole amide compounds for modulating human immune response
WO2025059546A1 (en) Proteolysis-targeting chimera tumor vaccine
US20230201339A1 (en) Use of thiazole amide compounds for modulating human immune response
KR20230084177A (ko) 결핵균 추출물의 신규 용도
JP2026509438A (ja) ポルフィリン及びその薬学的使用
Krishnamachari PLGA microparticle based vaccine carriers for an improved and efficacious tumor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260212